Neurology Central

Antibody show promise against multiple sclerosis

Published recently in the New England Journal of Medicine, three clinical trials conducted by a team of international researchers have demonstrated that orcrelizumab, a humanized monoclonal antibody that depletes CD20+ B cells, can slow the progression of primary progressive multiple sclerosis (MS) and reduce new attacks in patients with relapsing remitting MS. These new findings are a promising breakthrough for the treatment of MS; however, further research is required to govern the drug’s long-term safety and efficacy.
Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.